Beta Bionics to Present at the TD Cowen 46th Annual Health Care Conference
Beta Bionics, a leader in diabetes management solutions, announced it will present at TD Cowen’s 46th Annual Health Care Conference on March 4, 2026. The presentation will cover the company's pioneering work in advanced adaptive closed-loop algorithms, including its FDA-cleared iLet Bionic Pancreas. A live audio webcast will be available on the company's investor relations website.
BBNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics (NASDAQ: BBNX) following a significant stock drop. The investigation stems from the company's announcement on January 9, 2026, where it reported expectations of fewer patient starts in the fourth quarter than analysts had estimated, leading to a 37% decline in shares. The law firm is encouraging investors who suffered losses to contact them to discuss their legal rights regarding potentially misleading statements or undisclosed information by the company.
Stifel cuts Beta Bionics stock price target on guidance review
Stifel has reduced its price target for Beta Bionics (NASDAQ:BBNX) to $22 from $25, maintaining a Buy rating on the stock, citing a review of the company's 2026 guidance and recent financial disclosures. Despite a significant year-to-date decline and an FDA Warning Letter, Beta Bionics reported better-than-expected Q4 2025 gross margin and provided an aligned 2026 revenue and gross margin guidance. The company's next-generation Mint pump remains on track for a late 2027 launch, and analysts have varying perspectives on its market future.
Beta Bionics (BBNX) Revenue Growth Outpaces Persistent Losses And Tests Bullish Narratives
Beta Bionics (BBNX) reported Q4 2025 revenue of US$32.1 million and a net loss of US$13.5 million, contributing to a full-year revenue of US$100.3 million and a net loss of US$73.2 million. The company's revenue grew 53.9% year over year, a point highlighted by bullish investors who believe the iLet installed base and pharmacy reimbursement can sustain growth despite ongoing losses. Conversely, bearish investors point to persistent trailing losses and high operating expenses, arguing that profitability remains distant, while the company's 6x P/S multiple is seen as a reflection of the tension between strong growth and continued unprofitability.
Stifel cuts Beta Bionics stock price target on guidance review
Stifel lowered its price target on Beta Bionics (NASDAQ:BBNX) to $22 from $25, while maintaining a Buy rating, despite the stock's significant year-to-date decline and an oversold RSI. The adjustment follows the disclosure of Q4 2025 revenue and patient start data, along with 2026 guidance, and updates on the company's FDA Warning Letter and pipeline programs. Beta Bionics reported stronger-than-expected Q4 2025 gross margins and has a healthy financial position, with pipeline developments like the Mint pump and bihormonal program progressing.
Stifel cuts Beta Bionics stock price target on guidance review
Stifel has lowered its price target for Beta Bionics (NASDAQ:BBNX) shares from $25 to $22, while maintaining a Buy rating, following a review of the company's Q4 2025 results and 2026 guidance. Despite the price target cut, Beta Bionics reported strong Q4 2025 gross margins and its 2026 revenue and gross margin guidance aligned with or exceeded expectations. The company is also progressing with its next-generation pump and bihormonal programs, with Stifel anticipating market share gains.
TD Cowen cuts Beta Bionics stock price target on revenue timing
TD Cowen lowered its price target for Beta Bionics (NASDAQ:BBNX) to $16.00 from $17.00, while maintaining a Hold rating, citing revenue timing despite positive gross margins and strong annual revenue growth. The firm's assessment comes as Beta Bionics provided 2026 revenue guidance, aligning with consensus, and continues to advance its product pipeline with no timeline changes for its Mint or bihormonal programs. Other recent analyst actions include UBS initiating coverage with a Buy rating and Truist Securities lowering its price target due to market conditions and management concerns.
Beta Bionics (BBNX) Q4 2025 Earnings Transcript
Beta Bionics (BBNX) reported strong Q4 and full-year 2025 financial results, with net sales up 54% year-over-year to $100.3 million and Q4 revenue increasing 57% to $32.1 million, driven by patient adoption and pharmacy channel growth. The company also provided 2026 guidance, expecting continued revenue growth between $130 million and $135 million, alongside strategic expansions in its sales force and ongoing R&D for its Mint patch pump and bihormonal system. Beta Bionics addressed an FDA warning letter concerning complaint handling and quality systems, asserting remediation efforts are on track and do not impact product launch timelines.
Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026
Beta Bionics reported strong financial results for Q4 and full year 2025, with net sales reaching $32.1 million and $100.3 million respectively, driven by significant growth in the Pharmacy Benefit Plan channel. The company also provided optimistic guidance for full year 2026, estimating total revenue between $130 million and $135 million, while highlighting progress in its R&D pipeline, including the bihormonal system and Mint patch pump program. Sean Saint, Beta Bionics' President and CEO, emphasized the company's leadership in the insulin pump market and its commitment to innovation for diabetes management.
Beta Bionics Shares Edge Higher After Q4 Revenue Jumps 57%, Full-Year Sales Top $100 Million
Beta Bionics (Nasdaq: BBNX) saw its shares modestly rise after reporting strong quarterly and full-year financial results for 2025. The company's Q4 net sales surged 57% to $32.1 million, while full-year sales topped $100 million, largely driven by growth in both durable medical equipment and pharmacy benefit plan channels. Despite the revenue growth, the company's net loss widened for the full year, and adjusted EBITDA remained negative, yet management provided positive revenue guidance for 2026.
Beta Bionics, Inc. (BBNX) Reports Q4 Loss, Tops Revenue Estimates
Beta Bionics, Inc. (BBNX) reported a Q4 loss of $0.30 per share, outperforming the consensus estimate of a $0.42 loss, and posted revenues of $32.12 million, slightly exceeding estimates. Despite the strong quarterly performance, the company's shares have fallen significantly year-to-date, and its current outlook, based on unfavorable estimate revisions, translates to a Zacks Rank #4 (Sell), suggesting potential market underperformance.
Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026
Beta Bionics reported strong financial results for Q4 and full year 2025, with net sales reaching $32.1 million (up 57%) and $100.3 million (up 54%) respectively, driven by significant growth in the Pharmacy Benefit Plan channel. The company also provided optimistic guidance for full year 2026, estimating total revenue between $130 million and $135 million, alongside continued progress in its R&D pipeline including the bihormonal system and Mint patch pump program.
Earnings Preview For Beta Bionics
Beta Bionics (NASDAQ: BBNX) is scheduled to release its quarterly earnings report on Tuesday, February 17, 2026, with analysts forecasting an EPS of $-0.39. Historically, the company has beaten EPS estimates, leading to share price increases. Investors will be closely watching the guidance provided for the next quarter, as this often influences stock price more than the beat or miss itself.
BBNX SECURITIES ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP is investigating potential securities claims against Beta Bionics (NASDAQ: BBNX) after the company's stock plunged approximately 37% on January 9, 2026. This drop occurred following Beta Bionics' announcement that it expects fewer patient starts in the fourth quarter than analysts had estimated. The law firm is encouraging investors who have suffered significant losses to contact them to discuss their legal options.
UBS Group Upgrades Beta Bionics (NASDAQ:BBNX) to "Strong-Buy"
UBS Group has upgraded Beta Bionics (NASDAQ:BBNX) to a "strong-buy" rating, contributing to a "Moderate Buy" consensus among analysts with an average price target of $26.42. Following this news, BBNX stock rose 6.6% to open at $14.78. Despite some insider selling, major institutional investors have significantly increased their stakes in the company.
Beta Bionics (NASDAQ:BBNX) Trading Up 7.9% - Here's What Happened
Beta Bionics (NASDAQ:BBNX) saw its stock price trade up 7.9% on Tuesday, closing at $14.97, although trading volume was significantly lower than its average. Analyst coverage remains mixed, with an average "Moderate Buy" rating and a price target of $26.42. Insider selling has been noted recently, even as institutional investors increased their stakes in the company.
Essex Investment Management Co. LLC Takes Position in Beta Bionics, Inc. $BBNX
Essex Investment Management Co. LLC has acquired a new stake in Beta Bionics, Inc., purchasing 222,615 shares valued at approximately $4.42 million. This move comes despite recent insider selling by Beta Bionics' CFO and another insider, who collectively sold shares worth over $960,000. Analysts currently hold a "Moderate Buy" rating for Beta Bionics, with an average price target of $26.42, significantly higher than its current trading price of $13.87.
Will Beta Bionics, Inc. (BBNX) Report Negative Earnings Next Week? What You Should Know
Beta Bionics, Inc. (BBNX) is expected to report a year-over-year increase in earnings on higher revenues for the quarter ending December 2025. Despite analyst estimates being revised slightly lower, the company has a history of beating consensus EPS estimates in two of the last four quarters. However, a negative Earnings ESP and a Zacks Rank of #4 currently suggest it is difficult to definitively predict an earnings beat for the upcoming report.
Beta Bionics, Inc. (NASDAQ:BBNX) Given Average Recommendation of "Moderate Buy" by Brokerages
Thirteen brokerages have issued a "Moderate Buy" consensus rating for Beta Bionics, Inc. (NASDAQ:BBNX), with an average 12-month price target of $26.42. Key points include insider selling by CFO Stephen Feider, reducing his stake by 31.94%, and a current share price of $13.08, significantly below analyst targets, with recent adjustments to price objectives and ratings from various firms. The company, which specializes in automated insulin delivery solutions for type 1 diabetes, has a market cap of $575.85 million and a negative P/E ratio.
UBS initiates coverage on Beta Bionics stock with Buy rating
UBS initiated coverage on Beta Bionics (NASDAQ:BBNX) with a Buy rating and a $24 price target, citing the company's potential to disrupt the insulin pump market with its differentiated technology and projected double-digit revenue growth. Despite a recent slowdown in new patient starts and an FDA warning letter on quality reporting systems, UBS expects Beta Bionics to capture significant market share. The stock has experienced a price drop from its 52-week high, and its RSI suggests it is currently oversold.
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP is investigating potential legal claims against Beta Bionics (NASDAQ: BBNX) on behalf of investors who suffered significant losses. The investigation follows a 37% stock plunge on January 9, 2026, after the company announced lower-than-expected patient starts in the fourth quarter. Investors are encouraged to contact attorney Josh Wilson to discuss their options.
Beta Bionics, Inc.'s (NASDAQ:BBNX) Popularity With Investors Under Threat As Stock Sinks 58%
Beta Bionics, Inc. (BBNX) has seen its share price drop by a significant 58% in the last month and 44% over the year. Despite this dip, the company's price-to-sales (P/S) ratio of 6.6x remains high compared to the industry average of below 3x, primarily due to recent stellar revenue growth of 67%. However, analysts forecast significantly lower future revenue growth for Beta Bionics compared to the broader Medical Equipment industry, raising concerns about the sustainability of its high P/S ratio.
Beta Bionics, Inc.'s (NASDAQ:BBNX) Popularity With Investors Under Threat As Stock Sinks 58%
Beta Bionics Inc. (NASDAQ:BBNX) has seen its share price fall significantly by 58% in the last month, contributing to a 44% drop over the past year. Despite strong recent revenue growth of 67% and projected future growth of 38% per annum, analysts forecast this growth to be lower than the broader Medical Equipment industry. The company's high price-to-sales (P/S) ratio of 6.6x, compared to an industry median of 3x, suggests investors may be overly optimistic given the less confident analyst outlook and the stock's recent performance.
Beta Bionics, Inc.'s (NASDAQ:BBNX) Popularity With Investors Under Threat As Stock Sinks 58%
Beta Bionics, Inc. (NASDAQ:BBNX) has seen its stock price fall by 58% over the last month and 44% over the past year. Despite this significant drop and its elevated price-to-sales (P/S) ratio of 6.6x compared to an industry median below 3x, the company has shown strong recent revenue growth of 67%. However, analyst forecasts predict future revenue growth of 38% annually, which is materially lower than the industry's projected 126% growth, raising concerns about the sustainability of its high P/S ratio.
Truist Securities lowers Beta Bionics stock price target to $25 from $37
Truist Securities has lowered its price target for Beta Bionics (NASDAQ:BBNX) to $25 from $37, while maintaining a Buy rating. The adjustment reflects concerns over slowing Net Promoter Score momentum, recent waitlist issues, and general multiple compression in small-cap medical technology stocks. Despite these challenges, the firm sees long-term drivers intact, including increasing pharmacy channel penetration and anticipated FDA approval for its 'Mint' Patch Pump by 2026.
Truist Financial Has Lowered Expectations for Beta Bionics (NASDAQ:BBNX) Stock Price
Truist Financial has reduced its price target for Beta Bionics (NASDAQ:BBNX) from $37 to $25, maintaining a "buy" rating with an implied 80% upside. This adjustment comes amidst a "Moderate Buy" consensus from analysts with an average target of $27.18, though Bank of America recently downgraded the stock to "neutral." Insider selling has been observed, with two officers selling a significant number of shares, while institutional investors like Vanguard have substantially increased their holdings.
Beta Bionics receives FDA warning letter
Beta Bionics, the manufacturer of the iLet Bionic Pancreas, has received a warning letter from the FDA concerning non-conformities in its quality management system, medical device reporting, and correction and removals. Despite this, the company does not anticipate the letter will impact its ability to market or distribute products, nor will it affect the planned launch of a new insulin patch pump or its financial results. An analyst from Leerink Partners called the development "unwelcome" but noted management's confidence in avoiding disruption.
Truist Securities lowers Beta Bionics stock price target to $25 from $37
Truist Securities has lowered its price target for Beta Bionics (NASDAQ:BBNX) to $25 from $37, while maintaining a Buy rating. The reduction is attributed to a slowdown in Net Promoter Score momentum, recent waitlist concerns, and broader multiple compression in the small-cap medical technology sector. Despite these short-term challenges and the stock's current unprofitability, Truist Securities believes the long-term drivers for Beta Bionics remain strong, citing increasing pharmacy channel penetration and anticipated FDA approval for its 'Mint' Patch Pump.
BBNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics (NASDAQ: BBNX) on behalf of investors who suffered significant losses. This investigation follows a approximately 37% drop in Beta Bionics' stock on January 9, 2026, after the company announced lower-than-estimated patient starts for the fourth quarter. The firm encourages affected investors to contact them to discuss their legal rights.
FDA warning letter hits Beta Bionics (NASDAQ: BBNX) but Mint plan stands
Beta Bionics received a warning letter from the FDA on January 29, 2026, citing deficiencies in its quality management system, medical device reporting, and correction/removal processes following a June 2025 inspection. Despite this, the company maintains that the warning letter will not materially affect its guidance to launch commercialization of Mint by the end of 2027. Beta Bionics is implementing corrective actions and preparing a response, though it acknowledges the possibility of further regulatory action if issues are not resolved to the FDA's satisfaction.
Beta Bionics Receives FDA Warning Letter
Beta Bionics (BBNX) received a warning letter from the FDA on January 29, 2026, citing deficiencies in quality management and reporting at its Irvine facility. The company is implementing corrective actions, and the warning does not impact product production or marketing. Beta Bionics plans to launch "Mint" by the end of 2027.
BBNX Investors Have Opportunity to Join Beta Bionics, Inc. Fraud Investigation with the Schall ...
The Schall Law Firm is investigating claims on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX) for alleged securities law violations. This investigation follows the company's disclosure on January 8, 2026, that it anticipated fewer patient starts than analysts expected, leading to a more than 37% drop in share prices the next day. The firm encourages affected investors to contact them to discuss their legal rights.
BBNX Investors Have Opportunity to Join Beta Bionics, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Beta Bionics, Inc. (BBNX) on behalf of investors following a significant stock drop. This investigation was prompted by Beta Bionics' disclosure on January 8, 2026, that it expected fewer patient starts than analysts had projected, causing its shares to fall over 37%. The firm is looking into potential violations of securities laws, specifically whether the company issued false or misleading statements.
BBNX Investors Have Opportunity to Join Beta Bionics, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm has announced an investigation into Beta Bionics, Inc. (NASDAQ: BBNX) for potential securities law violations. This comes after Beta Bionics disclosed on January 8, 2026, that it expected fewer patient starts than analysts anticipated, leading to a over 37% drop in share price the following day. The firm is encouraging shareholders who suffered losses to participate in the investigation.
Beta Bionics stock initiated with Hold rating at TD Cowen By Investing.com
TD Cowen has initiated coverage on Beta Bionics (NASDAQ:BBNX) with a Hold rating and a $17.00 price target, noting the company's successful first year and 67% revenue growth. Despite positive revenue prospects driven by its iLet device and pipeline, TD Cowen's analysis suggests a potential deceleration in new prescription share gains. Other firms like Stifel and Piper Sandler have higher price targets and maintain positive outlooks, while BofA Securities downgraded Beta Bionics to Neutral due to valuation concerns.
Today's Analyst Rating: BBNX Receives 'Hold' Rating from TD Cowe
TD Cowen has initiated coverage on Beta Bionics (BBNX) with a 'Hold' rating and set a price target of USD 17.00. This new rating follows several recent 'Buy' ratings from other firms, with price targets ranging from USD 33.00 to USD 40.00. Beta Bionics specializes in medical devices for diabetes management, and the average analyst price target suggests a significant upside from its current market price.
Beta Bionics stock initiated with Hold rating at TD Cowen
TD Cowen initiated coverage on Beta Bionics (NASDAQ:BBNX) with a Hold rating and a $17.00 price target, acknowledging the company's strong revenue growth and iLet device adoption but expressing concerns about a potential deceleration in new prescription share gains. Other analysts have varying targets, with some significantly higher, while recent news highlights strong preliminary Q4 2025 revenue but a slight miss in new patient starts compared to Wall Street forecasts.
INVESTOR ALERT: Investigation of Beta Bionics, Inc. (BBNX) by Holzer & Holzer, LLC
Holzer & Holzer, LLC is investigating Beta Bionics, Inc. (BBNX) regarding potential violations of federal securities laws. This investigation follows Beta Bionics' announcement of preliminary unaudited fourth-quarter 2025 financial results, indicating new patient starts for its iLet Bionic Pancreas System are expected to fall below analyst estimates, which led to a drop in the company's stock price. Shareholders who experienced losses are encouraged to contact the law firm to discuss their legal rights.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Beta Bionics, Inc. (BBNX) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Beta Bionics, Inc. (BBNX) following a significant drop in its stock price. The investigation stems from Beta Bionics' disclosure on January 8, 2026, that it anticipated fewer patient starts than analysts had projected, causing shares to fall over 37% the following day. The legal firm is encouraging shareholders who purchased Beta Bionics securities to join the investigation.
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics, Inc. (NASDAQ: BBNX) following a significant stock decline on January 9, 2026. This decline occurred after the company disclosed preliminary fourth-quarter 2025 performance metrics, specifically lower-than-anticipated new patient starts for its iLet automated insulin delivery system, which fell short of market expectations. Investors who suffered significant losses are encouraged to contact the law firm to discuss their legal options.
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics (NASDAQ: BBNX) after the company's shares sharply declined on January 9, 2026. This drop occurred following Beta Bionics' disclosure of preliminary fourth-quarter 2025 performance metrics that fell short of market expectations, specifically due to lower-than-anticipated new patient starts for its iLet automated insulin delivery system. Investors who suffered significant losses are encouraged to contact the law firm to discuss their legal options.
BBNX FRAUD INVESTIGATION: Kaplan Fox Alerts Investors of Beta Bionics, Inc. (BBNX) to Potential Securities Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Beta Bionics, Inc. (NASDAQ: BBNX) after the company's Q4 2025 new patient starts fell short of analyst expectations, leading to a significant stock price decline. Investors who suffered losses are encouraged to contact Kaplan Fox for more information regarding the investigation. Beta Bionics is a medical device company known for its iLet Bionic Pancreas.
Beta Bionics, Inc. (BBNX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased Beta Bionics, Inc. (NASDAQ: BBNX) securities. This investigation follows the company's disclosure on January 8, 2026, where it anticipated fewer patient starts than analysts had projected, leading to a more than 37% drop in its share price the following day. Investors are encouraged to contact the law firm to learn more about participating in the investigation at no cost.
FinancialContent - BBNX FRAUD INVESTIGATION: Kaplan Fox Alerts Investors of Beta Bionics, Inc. (BBNX) to Potential Securities Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Beta Bionics, Inc. (BBNX) after the company's stock declined significantly following preliminary financial results. Beta Bionics, a medical device company, reported new patient starts for Q4 2025 that fell short of analyst expectations, leading to a 37% drop in share price. The law firm is alerting investors who suffered losses to contact them regarding the investigation.
BBNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics, Inc. (NASDAQ: BBNX) after its shares plunged approximately 37% on January 9, 2026. The investigation focuses on whether the company issued misleading statements or failed to disclose information relevant to investors, following Beta Bionics' announcement of fewer patient starts than analyst estimates for the fourth quarter. Investors who suffered significant losses are encouraged to contact the law firm to discuss their legal options.
BBNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics, Inc. (NASDAQ: BBNX) after the company's shares plunged approximately 37% on January 9, 2026. This drop occurred following Beta Bionics' announcement that it expected fewer patient starts in the fourth quarter than analysts had estimated. The law firm is encouraging investors who suffered significant losses to contact them for legal consultation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beta Bionics, Inc. - BBNX
Pomerantz LLP is investigating potential securities fraud claims against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of its investors. This investigation follows a significant 37.03% drop in Beta Bionics' stock price after the company reported preliminary Q4 2026 financial results showing a 36% year-over-year increase in new patient starts, a considerable decrease from the 68% growth in the prior quarter. Investors who believe they have been affected are encouraged to contact the law firm.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beta Bionics, Inc. - BBNX
Pomerantz LLP is investigating potential securities fraud claims against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of its investors. The investigation follows a 37.03% drop in Beta Bionics' stock price after the company reported a significantly lower year-over-year increase in new patient starts for the fourth quarter of 2026 compared to the prior quarter. Investors who suffered losses are encouraged to contact Pomerantz LLP for information on joining a potential class action lawsuit.
Kaplan Fox Reminds Investors of Beta Bionics, Inc. (BBNX) to an Investigation of Potential Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Beta Bionics, Inc. (NASDAQ: BBNX) after the company announced preliminary Q4 2025 financial results showing new patient starts below analyst expectations. This news led to a 37% drop in Beta Bionics' stock price. The law firm is seeking investors who suffered losses to join their investigation.
Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Beta Bionics, Inc. (NASDAQ: BBNX)
Scott+Scott Attorneys at Law LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) for potentially misleading investors with false statements and/or failing to disclose material information in violation of federal securities laws. This investigation follows Beta Bionics' preliminary fourth-quarter 2025 financial results, which showed new patient starts falling short of consensus expectations, leading to a significant drop in its stock price. The firm is seeking investors who purchased Beta Bionics common stock and suffered losses to join a potential class action.
